Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 13 of 13 for “"Myelosuppression"”.

  1. Lithium-Carbonate as a Protectant Against Chemotherapy-Induced Myelosuppression

    Lithium carbonate has been used as an adjunct to cancer chemotherapy to lessen the dose-limiting myelosuppressive effects of several anti-cancer drugs. Its mechanism is unknown, but several possible sites of action have been considered. Lithium causes a neutrophilia and may protect the bone marrow …

    uiuc Repository record for Lithium-Carbonate as a Protectant Against Chemotherapy-Induced Myelosuppression (opens in a new tab)

  2. ΑΝΑΛΥΣΗ ΤΩΝ ΑΛΛΗΛΕΠΙΔΡΑΣΕΩΝ ΑΝΘΡΑΚΥΚΛΙΝΩΝ-ΣΙΔΗΡΟΠΟΡΦΥΡΙΝΩΝ ΣΤΟ ΑΙΜΟΠΟΙΗΤΙΚΟ ΣΥΣΤΗΜΑ

    … USE IS LIMITED DUE TO THEIR BONE MARROW (MYELOSUPPRESSION) AND CARDIOVASCULAR TOXICITY. UNFORTUNATELY, IT HASN'T BEEN A UNIFIED THEORY TO EXPLAIN THE PLEOTROPIC EFFECTS OF ADR ON SEVERAL TISSUES. THE OBSERVATIONS THAT HEMIN (IRON-PROTOPORPHYRIN IX) COUNTERACTS ADR-INDUCED CYTOTOXICITY …

    greece Repository record for ΑΝΑΛΥΣΗ ΤΩΝ ΑΛΛΗΛΕΠΙΔΡΑΣΕΩΝ ΑΝΘΡΑΚΥΚΛΙΝΩΝ-ΣΙΔΗΡΟΠΟΡΦΥΡΙΝΩΝ ΣΤΟ ΑΙΜΟΠΟΙΗΤΙΚΟ ΣΥΣΤΗΜΑ (opens in a new tab)

  3. Synthesis of Paclitaxel Analogs

    … have been evaluated. In order to reduce the myelosuppression effect of the paclitaxel, several C3â ² and C4 paclitaxel analogs have been synthesized and their biological evaluation have been studied.

    vt Repository record for Synthesis of Paclitaxel Analogs (opens in a new tab)

  4. Oncogenic roles of RAS in acute myeloid leukemia cooperated with Mll-AF9.

    … significantly reduced aggressiveness, reduced myelosuppression and a more differentiated phenotype. We conclude that, in AML induced by an Mll-AF9 transgene, NRAS G12V expression contributes to acute leukemia maintenance by suppressing apoptosis and reducing differentiation of leukemia cells. …

    umn Repository record for Oncogenic roles of RAS in acute myeloid leukemia cooperated with Mll-AF9. (opens in a new tab)

  5. Examination of Transfusion Practice in Cancer Related Anemia in Northern Nevada, A Pilot Study

    … chemotherapy and/or radiation therapy related myelosuppression, disease process, hemorrhage, nutritional abnormalities, nephrotoxic interventions or hemolysis. The National Comprehensive Cancer Network (NCCN, 2013) recommends associated supportive transfusion therapy guidelines for symptomatic …

    unr Repository record for Examination of Transfusion Practice in Cancer Related Anemia in Northern Nevada, A Pilot Study (opens in a new tab)

  6. JAG1 Blockade With oHSV Polarizes Macrophages to Create a Unique Vulnerability for Cetuximab-Mediated Senolysis of Glioma Cells

    … (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells …

    uthsc Repository record for JAG1 Blockade With oHSV Polarizes Macrophages to Create a Unique Vulnerability for Cetuximab-Mediated Senolysis of Glioma Cells (opens in a new tab)

  7. The Development of a Novel Peptide-Drug Conjugate for Treating Triple-Negative Breast Cancer

    … severe side effects such as cardiotoxicity, myelosuppression, alopecia and gastrointestinal problems. A peptide-drug conjugate (PDC) targeting overexpressed epidermal growth factor receptor (EGFR) in TNBC cells was synthesized to increase the uptake of drug by TNBC cells, thereby improving …

    chapman Repository record for The Development of a Novel Peptide-Drug Conjugate for Treating Triple-Negative Breast Cancer (opens in a new tab)

  8. Comparison of two saline loading protocols for preventing nephrotoxicosis associated with high-dose cisplatin

    … toxicoses (fibrinonecrotic enteritis) and severe myelosuppression (leukopenia) were incompatible with patient survival and therefore, dose limiting. In another study we compared efficacy of hypertonic saline with normal saline in preventing nephrotoxicosis associated with administration of …

    vt Repository record for Comparison of two saline loading protocols for preventing nephrotoxicosis associated with high-dose cisplatin (opens in a new tab)

  9. Combination therapy studies with the vascular disruptive agent combretastatin-a4-phosphate (CA4P)

    … A5B7 combination therapy led to dose limiting myelosuppression with minimal efficacy at a 131I-A5B7 dose 66% of single agent antibody MTD. In UKCTC-207, 70% of patients either responded or had disease stability with symptomatic improvement. We also investigated whether CA4P effect is mediated …

    ucl Repository record for Combination therapy studies with the vascular disruptive agent combretastatin-a4-phosphate (CA4P) (opens in a new tab)

  10. Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor

    … effect of temzolomide-bevacizumab therapy was myelosuppression. We have designed a phase II study to evaluate the safety and efficacy of temozolomide-bevaciumab in locally advanced, recurrent, and metastatic HPC/SFT in a prospective manner. Combination therapy with temozolomide and bevacizumab …

    uthsc Repository record for Temozolomide and Bevacizumab Therapy In Advanced Hemangiopericytoma/ Solitary Fibrous Tumor (opens in a new tab)

  11. The Effects of Methyltransferase Genes on Human Haematopoietic Stem Cell Function

    … on HSPCs, which could lead to significant myelosuppression. Mutations in the gene DNMT3A are the most common in ARCH and are associated with haematological and non-haematological diseases with significant morbidity and mortality. The R882 mutation is the most common within DNMT3A, …

    cambridge Repository record for The Effects of Methyltransferase Genes on Human Haematopoietic Stem Cell Function (opens in a new tab)

  12. The Use of Preclinical Models to Improve the Treatment of Retinoblastoma

    … was effective. However both drugs cause myelosuppression and therefore administrating both of these drugs systemically is not possible. An alternative effective therapy in the clinic was the use of a subconjunctival administration. We thought if we could administer both drugs, one by …

    tenn-hsc Repository record for The Use of Preclinical Models to Improve the Treatment of Retinoblastoma (opens in a new tab)